WallStreetZenWallStreetZen

NASDAQ: ORMP
Oramed Pharmaceuticals Inc Stock

$2.82+0.10 (+3.68%)
Updated Mar 27, 2024
ORMP Price
$2.82
Fair Value Price
$0.29
Market Cap
$114.26M
52 Week Low
$1.67
52 Week High
$5.25
P/E
20.14x
P/B
0.7x
P/S
69.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.34M
Earnings
$5.53M
Gross Margin
100%
Operating Margin
564.33%
Profit Margin
412.3%
Debt to Equity
0.35
Operating Cash Flow
-$10M
Beta
0.91
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ORMP Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ORMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ORMP ($2.82) is overvalued by 856.69% relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ORMP ($2.82) is not significantly undervalued (856.69%) relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ORMP is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more ORMP due diligence checks available for Premium users.

Be the first to know about important ORMP news, forecast changes, insider trades & much more!

ORMP News

Valuation

ORMP fair value

Fair Value of ORMP stock based on Discounted Cash Flow (DCF)
Price
$2.82
Fair Value
$0.29
Overvalued by
856.69%
ORMP ($2.82) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORMP ($2.82) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

ORMP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
20.14x
Industry
14.3x
Market
44.45x
ORMP is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ORMP is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

ORMP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.7x
Industry
6.2x
ORMP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ORMP's financial health

Profit margin

Revenue
$0.0
Net Income
$13.3M
Profit Margin
0%
ORMP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ORMP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$220.6M
Liabilities
$57.7M
Debt to equity
0.35
ORMP's short-term assets ($162.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORMP's short-term assets ($162.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORMP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.4M
Investing
$30.0M
Financing
-$25.0M
ORMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ORMP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ORMP$114.26M+3.68%20.14x0.70x
IOBT$113.97M+2.67%-0.87x0.86x
ALLK$112.48M-0.78%-0.60x0.67x
SGMO$111.82M+3.65%-0.42x1.35x
IMUX$116.91M+1.56%-0.62x4.04x

Oramed Pharmaceuticals Stock FAQ

What is Oramed Pharmaceuticals's quote symbol?

(NASDAQ: ORMP) Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol ORMP. Oramed Pharmaceuticals stock quotes can also be displayed as NASDAQ: ORMP.

If you're new to stock investing, here's how to buy Oramed Pharmaceuticals stock.

What is the 52 week high and low for Oramed Pharmaceuticals (NASDAQ: ORMP)?

(NASDAQ: ORMP) Oramed Pharmaceuticals's 52-week high was $5.25, and its 52-week low was $1.67. It is currently -46.29% from its 52-week high and 68.86% from its 52-week low.

How much is Oramed Pharmaceuticals stock worth today?

(NASDAQ: ORMP) Oramed Pharmaceuticals currently has 40,519,160 outstanding shares. With Oramed Pharmaceuticals stock trading at $2.82 per share, the total value of Oramed Pharmaceuticals stock (market capitalization) is $114.26M.

Oramed Pharmaceuticals stock was originally listed at a price of $7.92 in May 1, 2007. If you had invested in Oramed Pharmaceuticals stock at $7.92, your return over the last 16 years would have been -64.39%, for an annualized return of -6.25% (not including any dividends or dividend reinvestments).

How much is Oramed Pharmaceuticals's stock price per share?

(NASDAQ: ORMP) Oramed Pharmaceuticals stock price per share is $2.82 today (as of Mar 27, 2024).

What is Oramed Pharmaceuticals's Market Cap?

(NASDAQ: ORMP) Oramed Pharmaceuticals's market cap is $114.26M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Oramed Pharmaceuticals's market cap is calculated by multiplying ORMP's current stock price of $2.82 by ORMP's total outstanding shares of 40,519,160.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.